Compounded vs Brand Tirzepatide: What You Need to Know

Quick answer: Brand tirzepatide is the FDA-approved drug sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight management), made by Eli Lilly. Compounded tirzepatide is prepared by a pharmacy rather than the brand manufacturer. The biggest change for 2026 is regulatory: the FDA declared the tirzepatide shortage resolved in late 2024, and since then pharmacies generally cannot compound copies of tirzepatide except for a documented, patient-specific clinical need. That makes the old "compounded is just a cheaper version" framing out of date.

Tirzepatide is one of the two medications FormBlends works with. Here is how the brand and compounded routes actually compare today.

Is compounded tirzepatide the same as Mounjaro or Zepbound?

No, and it is important to be precise. Mounjaro and Zepbound are specific FDA-approved products that went through clinical trials, manufacturing inspections, and label review. Compounded tirzepatide is made by a licensed pharmacy, and it is not an FDA-approved product, not tested as a finished product the way the brand was, and not guaranteed to match the brand's strength, purity, or inactive ingredients. Both are built around the drug tirzepatide, but "built around the same drug" is not the same as being interchangeable or equivalent.

What is the difference between compounded tirzepatide and Zepbound?

The core differences come down to approval, oversight, and now legality:

Why was compounded tirzepatide available, and what changed?

During the 2022 to 2024 shortage, federal law allowed pharmacies to compound versions of tirzepatide so patients could get treatment when the brand was hard to find. That is why compounded tirzepatide became widely advertised at lower prices.

In late 2024 the FDA removed tirzepatide from its drug shortage list, declaring the shortage resolved. After that, 503A pharmacies and 503B outsourcing facilities were given deadlines in early 2025 to stop making copies. Once a drug is off the shortage list, compounding "essentially a copy" of an approved drug is generally not permitted under sections 503A and 503B, except in narrow situations such as a prescriber documenting a clinical need for a customized formulation that differs from the commercial product. The practical result is that routine compounded tirzepatide is far more restricted now than it was in 2023.

Is there a generic tirzepatide?

No. There is no FDA-approved generic tirzepatide. Generics are approved through a specific FDA pathway and proven to match the brand. Compounded tirzepatide is not a generic, and the brand still holds patent protection, so an approved generic is not expected in the near term.

How well does tirzepatide work?

The evidence comes from Eli Lilly's brand-name trials. In the obesity trial that studied the drug class (SURMOUNT-1, Jastreboff 2022), adults on tirzepatide lost about 15.0% of body weight at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks, compared with placebo. In the head-to-head diabetes trial that studied the drug class (SURPASS-2, Frias 2021), tirzepatide lowered A1C and produced more weight loss than semaglutide 1 mg. These results describe the brand-name drug that was actually tested. Outcomes from any compounded preparation depend on its real strength and quality, which is exactly what is not independently verified for compounded products.

How does tirzepatide work?

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1. Acting on both slows stomach emptying, increases fullness, and improves how the body handles insulin and blood sugar. This dual action is linked to the strong weight-loss and glucose results seen in the trials.

What are the ingredients in tirzepatide?

The active drug is tirzepatide, a synthetic peptide. The brand products also contain specific inactive ingredients (buffers, stabilizers, and a tonicity agent) that were reviewed as part of approval. Compounded versions may use different inactive ingredients and concentrations, which can affect things like injection comfort and storage. This is one reason compounded and brand products should not be treated as identical.

Side effects: are they different?

The side effects of tirzepatide come from how the drug works, so the types are similar across formulations: nausea, diarrhea, vomiting, constipation, and reduced appetite, mostly mild to moderate and worst during dose increases. In SURMOUNT-1, nausea affected roughly 17% to 22% of brand-tirzepatide users depending on dose. Both the brand and compounded routes carry the rodent thyroid-tumor boxed warning and rare risks of pancreatitis, gallbladder problems, and dehydration-related kidney injury. With compounded products there is an added uncertainty: if strength or purity is off, dosing and side effects can be less predictable.

Which should you choose?

For most people in 2026, the brand-name route is the available, FDA-approved option, and insurance coverage (especially Mounjaro for diabetes) can lower the cost. Compounded tirzepatide is now limited to specific situations a prescriber can document, rather than a routine cheaper substitute. If cost is the barrier, it is worth comparing coverage, manufacturer savings programs, and other treatment options with a clinician. The FormBlends provider comparison tool and the semaglutide overview can help you see your choices side by side.

Frequently asked questions

Is compounded tirzepatide the same as Mounjaro? No. Mounjaro is an FDA-approved product; compounded tirzepatide is a pharmacy preparation that is not FDA-approved and is not tested as a finished product the same way.

Is compounded tirzepatide the same as Zepbound? No. Zepbound is the FDA-approved tirzepatide for weight management. Compounded versions are not equivalent and are now restricted after the shortage ended.

Is there a generic tirzepatide? No. There is no FDA-approved generic, and compounded tirzepatide is not a generic.

Why was compounded tirzepatide cheaper? It avoided brand development and marketing costs and was allowed during the shortage. With the shortage resolved, routine compounding of copies is generally no longer permitted.

Can I still get compounded tirzepatide in 2026? Only in limited circumstances, such as a documented patient-specific clinical need for a formulation different from the commercial product. The broad availability seen during the shortage has ended.

Does compounded tirzepatide work as well as brand? Its results depend on its actual strength and quality, which are not independently verified the way the brand was in trials, so equivalence cannot be assumed.

What is the difference in cost? Brand runs about $1,000 to $1,400 monthly without insurance, often much less with coverage. Compounded pricing was lower during the shortage, but availability is now restricted.

Is compounded tirzepatide FDA-approved? No. Compounded drugs are not FDA-approved. Only Mounjaro and Zepbound are approved tirzepatide products.

Sources

• FDA. Updates on tirzepatide shortage and compounding policy. https://www.fda.gov/drugs/drug-safety-and-availability/fdas-concerns-unapproved-glp-1-drugs-used-compounding
• American Pharmacists Association. FDA Clarifies Policies for Compounders as National GLP-1 Supplies Begin to Stabilize. https://www.pharmacist.com/Publications/Pharmacy-Today/Article/fda-clarifies-policies-for-compounders-as-national-glp-1-supplies-begin-to-stabilize
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
• Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021. https://pubmed.ncbi.nlm.nih.gov/33812497/
• FDA Prescribing Information, Zepbound (tirzepatide). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf